Comparing Proton to Photon Radiotherapy Plans: UK Consensus Guidance for Reporting Under Uncertainty for Clinical Trials.


Journal

Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902

Informations de publication

Date de publication:
07 2020
Historique:
received: 31 01 2020
revised: 11 03 2020
accepted: 30 03 2020
pubmed: 21 4 2020
medline: 2 3 2021
entrez: 21 4 2020
Statut: ppublish

Résumé

In the UK, the recent introduction of high-energy proton beam therapy into national clinical practice provides an opportunity for new clinical trials, particularly those comparing proton and photon treatments. However, comparing these different modalities can present many challenges. Although protons may confer an advantage in terms of reduced normal tissue dose, they can also be more sensitive to uncertainty. Uncertainty analysis is fundamental in ensuring that proton plans are both safe and effective in the event of unavoidable discrepancies, such as variations in patient setup and proton beam range. Methods of evaluating and mitigating the effect of these uncertainties can differ from those approaches established for photon therapy treatments, such as the use of expansion margins to assure safety. These differences should be considered when comparing protons and photons. An overview of the effect of uncertainties on proton plans is presented together with an introduction to some of the concepts and terms that should become familiar to those involved in proton therapy trials. This report aims to provide guidance for those engaged in UK clinical trials comparing protons and photons. This guidance is intended to take a pragmatic approach considering the tools that are available to practising centres and represents a consensus across multidisciplinary groups involved in proton therapy in the UK.

Identifiants

pubmed: 32307206
pii: S0936-6555(20)30153-9
doi: 10.1016/j.clon.2020.03.014
pii:
doi:

Substances chimiques

Protons 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

459-466

Subventions

Organisme : Cancer Research UK
Pays : United Kingdom
Organisme : Chief Scientist Office
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Auteurs

M Lowe (M)

Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, The University of Manchester, Manchester, UK. Electronic address: Matthew.Lowe2@christie.nhs.uk.

A Gosling (A)

Department of Radiotherapy Physics, University College London Hospitals NHS Foundation Trust, London, UK.

O Nicholas (O)

South West Wales Cancer Centre, Swansea Bay NHS Trust, Swansea, UK; Swansea University Medical School, Swansea University, Swansea, UK; National Radiotherapy Trials Quality Assurance Group, Velindre Cancer Centre, Cardiff, UK.

T Underwood (T)

Division of Cancer Sciences, School of Medical Sciences, The University of Manchester, Manchester, UK.

E Miles (E)

National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, Northwood, Middlesex, UK.

Y-C Chang (YC)

Department of Radiotherapy, University College London Hospitals NHS Foundation Trust, London, UK.

R A Amos (RA)

Proton and Advanced Radiotherapy Group, Department of Medical Physics and Biomedical Engineering, University College London, London, UK.

N G Burnet (NG)

Division of Cancer Sciences, School of Medical Sciences, The University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK.

C H Clark (CH)

National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, Northwood, Middlesex, UK.

I Patel (I)

Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, The University of Manchester, Manchester, UK.

Y Tsang (Y)

National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, Northwood, Middlesex, UK.

N Sisson (N)

National Radiotherapy Trials Quality Assurance Group, The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, UK.

S Gulliford (S)

Department of Radiotherapy Physics, University College London Hospitals NHS Foundation Trust, London, UK; Department of Medical Physics and Biomedical Engineering, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH